Ep 22: Think of post-market surveillance as a value adding business process

We often think of the post-market surveillance (PMS) process as a regulatory requirement for medical devices, especially because of the revised EU-MDR (and IVDR) regulations now in effect in the European Union.But it is more than compliance. According to Per Maegaard, PMS is not just an exercise in meeting regulatory requirements, but intelligence gathering that can help other functions including Marketing. We should think of the PMS process as a value-adding business process, which can provide insights about the real-world clinical experience with our medical device.About Per MaegaardPer Maegaard is currently Director and Lead Auditor at MQC, providing quality consulting, process optimization and auditing services to clients in the medical industry. He has 20+ years of professional experience in Quality and Post-Market Safety and Surveillance at leading multi-national companies such as Stryker, Smith & Nephew and Coloplast. As Director of Post Market Safety at Stryker’s Trauma/Extremity division in Europe, he was responsible for establishing a post-market surveillance program to comply with EU-MDR.About Let’s Talk Risk! with Dr. Naveen AgarwalLet’s Talk Risk! with Dr. Naveen Agarwal is a weekly live audio event on LinkedIn, where we talk about risk management related topics in a casual, informal way. Join us at 11:00 am EST every Friday on LinkedIn.DisclaimerInformation and insights presented in this podcast are for educational purposes only. Views expressed by all speakers are their own and do not reflect those of their respective organizations.If you enjoyed this episode, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe